Government News

- Read more about Bombay HC rejects petition of Sun Pharma for ceiling price of ciprofloxacin
Hon’ble Bombay high court rejects petition of Sun Pharmaceuticals Industries Ltd. filed against price fixing of Ciprofloxacin HCL Tablet 250 mg by National Pharmaceutical Pricing Authority (NPPA). Sun Pharma filed petition under paragraph 31 of the Drugs (Prices Control) Order, 2013 against notification S.O. No.1882(E) dated 13.07.2015 issued by the NPPA fixing the ceiling price of Ciprofloxacin.
- Read more about IPA recommends health ministry to fullstop speculation that referesher course to be started for Unqualified person to handle medical stores
The Indian Pharmaceutical Association (IPA) strongly opposes the ideas which arise through some recent news indicates that there have been discussion regarding enabling the unqualified persons to be "pharmacists" by initiating some training courses. IPA firmly stated that medical stores/pharmacies should be run only in presence and under supervision of qualified, registered pharmacists.
- Read more about Manufacturing and sale licences once issued, shall remain valid forever : DTAB
In 74th meeting of Drugs Technical Advisory Board (DTAB), committee agreed for the proposal that the manufacturing and sale licences once issued, shall remain valid forever, unless suspended or cancelled by the Licensing Authority.
- Read more about AiMeD Applauds Government's Move of Asking RBI to Examine Foreign Investments in Medical Devices Sector
The Association of Indian Medical Device Industry (AiMeD) has applauded Govt’s move that comes in the wake of Finance Ministry urging RBI to undertake an audit of all investments made in medical device sector over policy loopholes and confusion over definitional distinction between medical device and pharma sector leading to increased vulnerability of Indian pharma companies and no real gains for domestic medical device manufacturing.
- Read more about US regulatory department fires generic pharmaceutical companies
The US regulatory department is all set to launch criminal report against 14 generic pharmaceuticals for conspiring to set medicine prices.
- Read more about Over-dependence on China for key pharma raw material worrying
India may have emerged as a key supplier of generic and affordable medicine for the world market, its overwhelming dependence on China for a crucial raw material , known as Active Pharmaceutical Ingredient (API)to the extent of over 65 percent of the requirement, has emerged as a main worrying area.
- Read more about DCGI extends validity of approval of BA/BE Centre
DCGI (Drugs Controller General of India) extends validity of approval of Bioavailability and Bioequivalence Centre from one year to three years to facilitate ease of working.
- Read more about 32 crore persons to be screened for Leprosy in India : Health Ministry
In line with the vision of Shri Narendra Modi, Hon’ble Prime Minister of India to eradicate Leprosy from India, Shri J P Nadda, Union Minister of Health and Family Welfare reviewed the National Leprosy Eradication Programme and pursuant to that, Ministry of Health and Family Welfare has launched the biggest Leprosy Case Detection Campaign (LCDC) in the country on 5th September 2016 across 149 districts of 19 states/UTs.
- Read more about Promotion and Regulation should go hand in hand for medical devices sector to provide affordable health care to the poor : Ananth Kumar
The Union Minister for Chemicals & Fertilizers and Parliamentary Affairs Sh. Ananth Kumar has said that Promotion and Regulation should go hand in hand for medical devices sector to provide affordable health care to the poor. Speaking at the 9th Medical Technology Conference in New Delhi today he said that regulation is required in the medical devices sector to check profit and money making so as to facilitate providing adequate medical facilities to the poor.
- Read more about Government of India simplifies rules to rise clinical trials
The Indian Health ministry has taken different steps to ease the conductance of clinical trials in India by creating strong regulatory platform for ensuring safety, rights and well beings of the clinical research.